Imugene Ltd
ASX:IMU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Imugene Ltd
Free Cash Flow
Imugene Ltd
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Imugene Ltd
ASX:IMU
|
Free Cash Flow
-AU$59.7m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-41%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Free Cash Flow
-$60.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Free Cash Flow
$2.5B
|
CAGR 3-Years
59%
|
CAGR 5-Years
2%
|
CAGR 10-Years
10%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Free Cash Flow
-AU$7.3m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Free Cash Flow
-AU$73.3m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Free Cash Flow
-AU$66.2m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-57%
|
|
Imugene Ltd
Glance View
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The firm is engaged in developing immunotherapies that seeks to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness the body’s immune system against cancerous tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with care drugs and immunotherapies such as chimeric antigen receptor T cells (CAR T’s) for solid tumors. Its PD-1 B-cell immunotherapy, known as PD1-Vaxx, aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies for the treatment of cancers. Its clinical trial candidates include VAXinia (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.
See Also
What is Imugene Ltd's Free Cash Flow?
Free Cash Flow
-59.7m
AUD
Based on the financial report for Dec 31, 2025, Imugene Ltd's Free Cash Flow amounts to -59.7m AUD.
What is Imugene Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-41%
Over the last year, the Free Cash Flow growth was 63%. The average annual Free Cash Flow growth rates for Imugene Ltd have been -13% over the past three years , -37% over the past five years , and -41% over the past ten years .
